Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). The drug combines serotonin reuptake inhibition and modulation of dopamine and serotonin receptors. As of July 2017, it is in preregistration in Japan for the treatment of MDD.